Opzelura Ruxolitinib 1.5% Cream in Pakistan | Well Mart

Introduction

Opzelura Ruxolitinib 1.5% Cream is a prescription topical medication containing ruxolitinib, a Janus kinase (JAK) inhibitor. It is used topically for specific inflammatory skin conditions, including mild-to-moderate atopic dermatitis and nonsegmental vitiligo according to current U.S. prescribing information.

Key Ingredient

Ruxolitinib: A JAK inhibitor that works by interfering with signaling pathways involved in immune and inflammatory responses in the skin. Opzelura contains 1.5% ruxolitinib.

Active Ingredient

• Ruxolitinib — 1.5% cream

• Each gram contains 15 mg of ruxolitinib

How It Works

Ruxolitinib inhibits Janus kinase (JAK) signaling pathways that are involved in inflammatory and immune responses. By acting locally on these pathways, Opzelura helps reduce the inflammatory activity associated with the conditions for which it is prescribed.

Who Can Use It

Opzelura is prescribed for specific patients with mild-to-moderate atopic dermatitis and for nonsegmental vitiligo. The current U.S. label allows use for atopic dermatitis in non-immunocompromised adults and children 2 years and older, and for nonsegmental vitiligo in adults and children 12 years and older. Use should be determined by a qualified healthcare professional.

How to Use

Use Opzelura exactly as prescribed by your healthcare professional. For atopic dermatitis, the FDA label directs application of a thin layer twice daily to affected areas covering up to 20% of body surface area. For nonsegmental vitiligo, apply a thin layer twice daily to affected areas covering up to 10% of body surface area. Do not use with occlusive dressings. Wash hands after application unless the hands are being treated.

Important Precautions

Opzelura carries important safety warnings because it is a JAK inhibitor. The prescribing information includes warnings concerning serious infections, malignancies, major cardiovascular events, thrombosis, and blood-cell abnormalities. It should not be combined with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine unless specifically directed by a healthcare professional.

Why Choose This Product

Opzelura provides a targeted topical formulation of ruxolitinib 1.5% for specific prescription indications. Unlike corticosteroid creams, ruxolitinib is a JAK inhibitor that works through JAK signaling pathways involved in inflammatory and immune responses.